Remission of a chemotherapy resistant tumor of low malignant potential with tamoxifen.
Low Malignant Potential (LMP) tumor of the ovary represents 15% of all ovarian tumors. The prognosis is excellent even in patients with extensive tumor involvement. However 20% of the patients die of disease in a 20 year period. Management of patients after surgery is not defined. Chemotherapy has shown response rates of 20% but no improvement in survival. Toxicity has been reported. We present a case of chemotherapy resistant LMP tumor with serologic response to tamoxifen, no evidence of disease and an excellent quality of life. Hormonal therapy may be considered in the treatment of LMP tumors.
Llerena
E
E
Hospital Universitario, Monterrey, Mexico.
Kudelka
A P
AP
Tornos
C
C
Cedillo
G F
GF
Lopez
A
A
Edwards
C L
CL
Litam
J P
JP
Kavanagh
J J
JJ
D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D018394:CA-125 Antigen / Q000097:blood; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D013629:Tamoxifen / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D018394:CA-125 Antigen; D013629:Tamoxifen